CAMBRIDGE, Mass., Feb. 7, 2024
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN)
("NeuroSense"), a company developing treatments for severe
neurodegenerative diseases, today announced that it has received
notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the
Company that it has regained compliance with the minimum bid price
requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for
continued listing.
To regain compliance with the Rule, the Company's ordinary
shares were required to maintain a minimum closing bid price of
$1.00 or more for at least 10
consecutive business days, which was achieved on February 6, 2024. Therefore, the Nasdaq Listing
Qualifications Staff considers the prior bid price deficiency
matter now closed.
NeuroSense's CEO, Alon Ben-Noon said, "Regaining compliance
with the Nasdaq minimum bid price listing requirement is an
important event as we continue to focus on the advancement of
PrimeC following the recently announced positive top-line results
from the Phase 2b PARADIGM trial. We
are looking forward to reporting results from our collaboration
with Biogen in the coming weeks, evaluating the impact of PrimeC on
neurofilament levels in participants enrolled in PARADIGM."
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding the timing for release of results
from the Company's strategic collaboration with Biogen. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. The future events
and trends may not occur and actual results could differ materially
and adversely from those anticipated or implied in the forward
looking statements. These risks include unexpected R&D costs or
operating expenses, a delay in the reporting of additional results
from PARADIGM clinical trial, a delay in the reporting of results
from the Company's strategic collaboration with Biogen, the
timing of expected regulatory and business milestones, risks
associated with meeting with the FDA to determine the best path
forward following the results from PARADIGM clinical trial,
including a delay in any such meeting, a delay in patient
enrollment for a Phase 2 trial for Alzheimer's disease or its
planned Phase 3 pivotal ALS trial of PrimeC; the potential for
PrimeC to safely and effectively target ALS; preclinical and
clinical data for PrimeC; the uncertainty regarding outcomes and
the timing of current and future clinical trials; timing for
reporting data; the development and commercial potential of any
product candidates of the company; and other risks and
uncertainties set forth in NeuroSense's filings with the Securities
and Exchange Commission (SEC). You should not rely on these
statements as representing our views in the future. More
information about the risks and uncertainties affecting the Company
is contained under the heading "Risk Factors" in the Annual Report
on Form 20-F filed with the Securities and Exchange Commission on
March 22, 2023. Forward-looking
statements contained in this announcement are made as of this date,
and NeuroSense Therapeutics Ltd. undertakes no duty to update such
information except as required under applicable law.
Logo:
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule-302056171.html
SOURCE NeuroSense